Integrum AB: Invitation to the Third Quarter 2023/24 Results Presentation
Mölndal, Sweden – February 23, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its third quarter 2023/24 results on February 29, 2024 at 14:00 CEST.
Integrum’s CEO Rickard Brånemark will present the report together with CFO Jörgen Svanström and US President Jeffrey Zanni in a webcast. The presentation will be held in English.
Time: Thursday, February 29, 2024 at 14:00 CEST.
Location: Webcast (see link below).
The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/
The webcast and presentation material will be accessible via https://www.finwire.tv/webcast/integrum/q3-presentation-2023/ where it is also possible to ask questions.
For more information, please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.
ABOUT INTEGRUM
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.